What Has Driven the Growth of the Carbapenem-Based Antibiotics Market in Recent Years?
The carbapenem-based antibiotics market has seen considerable growth due to a variety of factors.
•Steady growth has been observed in the size of the carbapenem-based antibiotics market in recent times. Projected to rise from $4.6 billion in 2024, it is expected to reach $4.82 billion by 2025, registering a compound annual growth rate (CAGR) of 4.8%.
The historical growth can be owed to factors such as epidemics and pandemics, escalation in chronic diseases, development in healthcare infrastructure, swift urbanization, natural disasters, and health emergencies.
What is the Market Size Forecast for the Carbapenem-Based Antibiotics Market?
The carbapenem-based antibiotics market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations are high for the carbapenem-based antibiotics market to experience robust growth in the coming years, with projections to reach $6.09 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%.
The predicted growth during the forecast period is due to the rising number of hospital-acquired infections, the emergence of antibiotic resistant strains, an increasing elderly population, a surge in surgical procedures, rising infectious diseases, and shifting demographics. The forecast period is also anticipated to witness trends such as strengthened supply chain resilience and security, development of alternative treatments, a move towards outpatient settings, growing knowledge about antimicrobial stewardship, and the upswing of precision medicine strategies.
What Are The Core Factors Supporting Growth In The Carbapenem-Based Antibiotics Market?
The rise in bacterial infections is predicted to stimulate the expansion of the carbapenem-based antibiotics market. Bacterial infections are diseases brought on by microscopic organisms known as bacteria that can attack the body and result in various ailments and symptoms. Carbapenem-based antibiotics are utilized to handle severe or antibiotic-resistant bacterial infections, which include those triggered by gram-positive and gram-negative bacteria. As an illustration, a report by the Centers for Disease Control and Prevention, a government agency in the US, stated in July 2024 that during 2023, 78% of all bacterial infections were detected by CIDTs in the historical catchment area, and 46% were diagnosed solely using CIDTs. Consequently, the escalating occurrence of bacterial infections is facilitating the amplification of the carbapenem-based antibiotics market.
What Are The Major Segments Within The Global Carbapenem-Based Antibiotics Market?
The carbapenem-based antibiotics market covered in this report is segmented –
1) By Type: Meropenem, Imipenem, Doripenem, Tebipenem, Other Types
2) By Indication: Intra-abdominal Infections, Urinary Tract Infections, Pneumonia, Bacterial Meningitis, Skin And Skin Structure Infections, Acute Pelvic Infections, Prophylaxis of Surgical Site Infection, Respiratory Tract Infections, Gynecological Infections, Other Indications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Meropenem: Meropenem Injection, Meropenem and Vaborbactam Combination, Meropenem for Pediatric Use
2) By Imipenem: Imipenem and Cilastatin Combination, Imipenem and Relebactam Combination, Imipenem Monotherapy
3) By Doripenem: Doripenem Injection, Doripenem for Complicated Infections
4) By Tebipenem: Tebipenem for Oral Administration, Tebipenem Pediatric Formulations, Tebipenem for Resistant Infections
5) By Other Types: Ertapenem, Panipenem, Faropenem, Combinations with Beta-Lactamase Inhibitors
Pre-Book The Carbapenem-Based Antibiotics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The Carbapenem-Based Antibiotics Market?
The growing trend of product innovations is changing the landscape of the carbapenem-based antibiotics market. Companies leading this market are continuously developing innovative products to maintain their market stand. In line with this, the National Health Service (NHS), a government institution of the UK, rolled out a revolutionary subscription program for antibiotics, in partnership with the pharmaceutical industry, to tackle antimicrobial resistance (AMR) in August 2024. Revealed on August 12, 2024, this creative modus operandi enables pharmaceutical companies to procure annual fixed payments of up to £20 million per drug, irrespective of the prescription volume, thereby eradicating the incentives for over-prescription. This venture, worth an estimated £1.9 billion over a span of 16 years, is designed to promote the creation of new antibiotics by assuring financial feasibility for pharmaceutical corporations. Following a prosperous trial phase, this project fits into the UK's extensive scheme to address AMR, a burgeoning global health hazard with the potential to cause millions of fatalities by 2050 if not mitigated. The WHO-identified critical pathogens will be specifically targeted by the NHS, underlining its determination for responsible antibiotic management and innovation in antibiotic research and development.
Who Are the Key Players in the Carbapenem-Based Antibiotics Market?
Major companies operating in the carbapenem-based antibiotics market include:
• Pfizer Inc.
• Merck & Co. Inc.
• Fresenius Kabi LLC
• GlaxoSmithKline Plc
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• AstraZeneca plc
• Meiji Holdings Co. Ltd.
• Sandoz International GmbH
• Sumitomo Dainippon Pharma Co. Ltd.
• Shionogi & Co Ltd.
• Aurobindo Pharma Ltd.
• Acurx Pharmaceuticals LLC
• Daewoong Pharmaceutical Co. Ltd.
• CeramTec GmbH
• ACS Dobfar S.p.A
• JW Pharmaceutical Corp
• Centrient Pharmaceuticals Co
• Spero Therapeutics Inc.
• Kopran Limited
• Savior Lifetec Corporation
• Flagship Biotech International Pvt. Ltd.
• Iterum Therapeutics plc
• Cam Carbapenem-based antibiotics BV
• Intelicure Lifesciences
• Ikeda Corporation
What Is The Most Dominant Region In The Carbapenem-Based Antibiotics Market?
North America was the largest region in the Carbapenem-Based Antibiotics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carbapenem-based antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
